BLACKSBURG, Va., May 28 -- Virginia Polytechnic Institute and State University issued the following news release:
Histotripsy not only works against targeted tumors, but may also trigger an immune response against tumors elsewhere in the body.
That was a finding in the 2018 Theresa Study, the first-ever trial of histotripsy - a noninvasive tumor-destruction technique using focused ultrasound waves - in human patients.
Now, new research led by Virginia Tech seeks to take that discovery a step further.
This research, funded by a $419,080 grant from the National Cancer Institute, combines histotripsy with an immune-stimulating compound to treat osteosarcoma, an aggressive bone cancer that carries a grim prognosis for people and dogs.
"I h...